The impact of pharmacogenetics on HIV therapy. - Wikidata - awgldk - TriplyDB

The impact of pharmacogenetics on HIV therapy.

The impact of pharmacogenetics on HIV therapy.

http://www.wikidata.org/entity/Q37405140

about

Genetic correlates influencing immunopathogenesis of HIV infection Individualization of antiretroviral therapy--pharmacogenomic aspect Genetic variants of APOC3 promoter and HLA-B genes in an HIV infected cohort in northern South Africa: a pilot study.Analysis of pharmacogenetic traits in two distinct South African populations Pharmacokinetic optimization of antiretroviral therapy in children and adolescents.Priority pharmacogenetics for the African continent: focus on CYP450.Pharmacogenetics of CYP2B6, CYP2A6 and UGT2B7 in HIV treatment in African populations: focus on efavirenz and nevirapine.Strengths, weaknesses, opportunities and challenges for long acting injectable therapies: Insights for applications in HIV therapy.The impact of SLCO1B1 polymorphisms on the plasma concentration of lopinavir and ritonavir in HIV-infected men.Association between ABCC2 polymorphism and lopinavir accumulation in peripheral blood mononuclear cells of HIV-infected patients.Physiologically based pharmacokinetic models for the optimization of antiretroviral therapy: recent progress and future perspective

P2860

Q26827459-94B2F0D3-09F1-47BF-842F-E49925209DC7 Q28070574-61ADDE3A-91AC-42FF-9476-F26A07CDC76B Q34072196-CE23C0C9-CA54-4B84-8116-C7ADADAC6278 Q36475143-34DB7438-267D-4DB8-B7A2-FBF6254523C3 Q37835819-55E28928-5592-4AAF-A320-75FA90EE11F0 Q38188600-63C695C5-53F6-4D06-827C-75F457308D69 Q38267710-5E75C4C1-A73D-4723-84CE-D0E418081AB7 Q38750666-2CB7A2C6-848B-4373-9C01-9DA61465DEC9 Q39349116-A8A66D26-2634-4B46-8924-CD98D46D3023 Q43258274-BFF82217-3F6B-48A2-9C68-4B276F6D3E58 Q58073610-DBC8F44C-C410-4650-AF52-5F3B10273F5C

P2860

The impact of pharmacogenetics on HIV therapy.

http://www.wikidata.org/entity/Q37405140

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on March 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

The impact of pharmacogenetics on HIV therapy.

@en

The impact of pharmacogenetics on HIV therapy.

@nl

type

label

The impact of pharmacogenetics on HIV therapy.

@en

The impact of pharmacogenetics on HIV therapy.

@nl

prefLabel

The impact of pharmacogenetics on HIV therapy.

@en

The impact of pharmacogenetics on HIV therapy.

@nl

P1433

Q37405140-ED60C199-8832-4B01-BDA7-10ECEEFB4410

P1476

Q37405140-43DA6A16-8C5E-410E-B482-406F7414743D

P2093

Q37405140-3486C557-018D-4BBA-A611-F39D9D18F6AB

Q37405140-61F0DE86-6963-4892-83D0-B437D2296D87

Q37405140-C0121226-F187-40F2-BDF8-EE3176CBA3EE

P2860

Q37405140-05E05BBD-7E2F-4260-9925-CE2729F7D184

Q37405140-0A50065A-8C68-4C7F-A077-D13DDA375C6B

Q37405140-0CA78BC1-1EB6-4AEB-B817-B32B05A4EA88

Q37405140-0FFF8EE1-C5AA-49D2-BA34-DD9EE8BAE558

Q37405140-1075D237-54C0-4809-98B8-51DD84AE128B

Q37405140-16F1C8A8-027F-4771-8FA5-DFF1A88F8423

Q37405140-18635FA0-216B-487D-B7FC-51EE4875BC2F

Q37405140-1ABEB9C2-4CE5-4D43-9369-66410DF728E3

Q37405140-1AF5EFCE-4893-4193-9E34-C22447F37887

Q37405140-1B67AC71-256A-4375-9E51-F632F2500977

P304

Q37405140-879915A4-86E4-43CA-86B8-227C3431C168

P31

Q37405140-6C9F00EF-86F1-484A-B660-0BB5A78261C2

P356

Q37405140-BA851D33-EF4B-41B2-BA9A-FD62F19AF154

P433

Q37405140-96AE6501-E11F-4728-96D0-3F0925306E37

P478

Q37405140-EE1F1C02-0B6B-49D3-98B3-5F70AABB4399

P50

Q37405140-EBCDE2F9-AF98-4F53-BF34-0E8789BD979E

P577

Q37405140-470B558C-C0E8-461F-96B5-A6ACBB54DFC3

P698

Q37405140-FF931398-957D-46C3-AEEB-C1504900C052

P921

Q37405140-30F7B14C-2BFC-460B-8A0A-559B03B77D97

P356

IJSA.2008.008369

P1433

International Journal of STD & AIDS

P1476

The impact of pharmacogenetics on HIV therapy.

@en

P2093

D J Back

http://www.w3.org/2001/XMLSchema#string

M A Johnson

http://www.w3.org/2001/XMLSchema#string

T W Mahungu

http://www.w3.org/2001/XMLSchema#string

P2860

Circulating metabolites of the human immunodeficiency virus protease inhibitor nelfinavir in humans: structural identification, levels in plasma, and antiviral activities

Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues

A haplotype map of the human genome

Apolipoprotein E: far more than a lipid transport protein

Orosomucoid (alpha1-acid glycoprotein) plasma concentration and genetic variants: effects on human immunodeficiency virus protease inhibitor clearance and cellular accumulation

Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C-->T polymorphism at the multidrug resistance gene 1

Multidrug resistance-associated protein 2 (MRP2) affects hepatobiliary elimination but not the intestinal disposition of tenofovir disoproxil fumarate and its metabolites

A "silent" polymorphism in the MDR1 gene changes substrate specificity

Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients.

Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy.

P304

145-151

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1258/IJSA.2008.008369

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19255258

http://www.w3.org/2001/XMLSchema#string

P921